Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years

• Main Authors: Ivette Maldonado (Author), Manuel Plata (Author), Mauricio Gonzalez (Author), Alfonso Correa (Author), Claudia Nossa (Author), Anna R. Giuliano (Author), Elmar A. Joura (Author), Alex Ferenczy (Author), Brigitte M. Ronnett (Author), Mark H. Stoler (Author), Hao Jin Zhou (Author), Amita Joshi (Author), Rituparna Das (Author), Oliver Bautista (Author), Thomas Group (Author), Alain Luxembourg (Author), Alfred Saah (Author), Ulrike Kirsten Buchwald (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Among women aged 27-45 years, the quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic in the placebo-controlled FUTURE III study (NCT00090220; n = 3253). The qHPV vaccine was also generally well tolerated and highly immunogenic i...